MedTrace Logo

Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients

NCT00044720 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 484

Last updated 2009-08-18

No results posted yet for this study

Summary

The incidence of efficacy failure at 12 months between two regimens.

Conditions

  • Chronic Kidney Failure
  • Graft vs Host Disease
  • Kidney Transplantation

Interventions

DRUG

Rapamune

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Medical Monitor, MD · Wyeth is now a wholly owned subsidiary of Pfizer

Study Design

Allocation
RANDOMIZED
Masking
NONE

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2005-07-31
Completion
2005-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00044720 on ClinicalTrials.gov